Open AccessNeutralizing complement resistance improves cell-mediated killing (CDCC) of HER2 positive breast cancer cells by Trastuzumab and Pertuzumab
Author(s) -
Srinivas Mamidi,
Hoene Simon,
Michael Kirschfink
Publication year - 2013
Publication title -
frontiers in immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.646
H-Index - 124
ISSN - 1664-3224
DOI - 10.3389/conf.fimmu.2013.02.00959
Subject(s) - complement dependent cytotoxicity , skbr3 , pertuzumab , cancer research , cd59 , cancer cell , cytotoxicity , trastuzumab , chemistry , antibody , biology , complement system , microbiology and biotechnology , medicine , monoclonal antibody , immunology , cancer , antibody dependent cell mediated cytotoxicity , breast cancer , in vitro , biochemistry , human breast